editorials · reviews · multicenter studies · meta-analyses · randomized controlled trials · retractions
Sci Transl Med · Mar 2013
Protein replacement therapies for rare monogenic diseases have a higher probability of regulatory approval compared with biologics, small molecules, and grant-funded orphan drugs.
read on… or not…
We guarantee your privacy. Your email address will not be shared.
Receive a weekly email with the highest quality and most significant abstracts from critical care specialties.
Anesthesiology, Critical Care Medicine, Emergency Medicine, Medicine, and Pain medicine.
Includes a free 21 day trial of metajournal premium
We guarantee your privacy. Your email address will not be shared. Unsubscribe anytime.